Yeji
FDA approvalconf 0.98

iluvien — FDA approval

$ANIP · ANI PHARMACEUTICALS INC · chronic non-infectious uveitis affecting the posterior segment of the eye
Event date
March 14, 2025
449 days ago
Sponsor runway
cash-flow +
$311.2M liquid

Evidence

“the U.S. Food and Drug Administration has approved an expanded label for ILUVIEN ® (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye”
Source: 8-K filed 2025-03-14View on EDGAR ↗0001023024-25-000021

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

15 insiders · 0 buys · 14 sells
Grant
2025-05-22
Leonard Matthew J
Director
4,336 @ ——
Grant
2025-05-22
Walsh Patrick D
Director
4,336 @ ——
Grant
2025-05-22
Pera Antonio R
Director
4,336 @ ——
Grant
2025-05-22
TANNENBAUM RENEE P
Director
4,336 @ ——
Grant
2025-05-22
Thoma Jeanne
Director
4,336 @ ——
Grant
2025-05-22
HAUGHEY THOMAS
Director
4,336 @ ——
Sell
2025-05-15
Gutwerg Ori
SVP, GENERICS
881 @ $60.07$53K
Sell
2025-05-14
Mutz Christopher
HEAD OF RARE DISEASE
4,000 @ $60.45$242K
Sell10b5-1
2025-05-13
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
400 @ $62.20$25K
Sell10b5-1
2025-05-09
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
700 @ $76.83$54K
Sell10b5-1
2025-04-14
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
400 @ $68.96$28K
Tax
2025-03-23
Lalwani Nikhil
PRESIDENT & CEO
17,455 @ $64.26$1.12M
Tax
2025-03-23
CAREY STEPHEN P.
SVP & CFO
6,210 @ $64.26$399K
Sell10b5-1
2025-03-19
Davis Krista
SVP, CHIEF HR OFFICER
1,866 @ $65.00$121K
Sell10b5-1
2025-03-13
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
400 @ $63.33$25K
Tax
2025-03-07
CAREY STEPHEN P.
SVP & CFO
5,150 @ $60.62$312K
Tax
2025-03-07
Mutz Christopher
HEAD OF RARE DISEASE
2,874 @ $60.62$174K
Sell10b5-1
2025-03-07
Davis Krista
SVP, CHIEF HR OFFICER
1,000 @ $60.86$61K
Tax
2025-03-07
Lalwani Nikhil
PRESIDENT & CEO
17,060 @ $60.62$1.03M
Tax
2025-03-07
Gutwerg Ori
SVP, GENERICS
3,314 @ $60.62$201K
Sell
2025-03-05
Gutwerg Ori
SVP, GENERICS
300 @ $60.03$18K
Exercise
2025-03-05
Gutwerg Ori
SVP, GENERICS
300 @ $31.49$9K
Sell
2025-03-05
Gutwerg Ori
SVP, GENERICS
5,084 @ $60.00$305K
Tax
2025-02-28
Gutwerg Ori
SVP, GENERICS
1,570 @ $61.89$97K
Tax
2025-02-28
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
1,099 @ $61.89$68K
Tax
2025-02-28
CAREY STEPHEN P.
SVP & CFO
1,861 @ $61.89$115K
Tax
2025-02-28
Davis Krista
SVP, CHIEF HR OFFICER
1,099 @ $61.89$68K
Tax
2025-02-28
Lalwani Nikhil
PRESIDENT & CEO
12,216 @ $61.89$756K
Tax
2025-02-28
Mutz Christopher
HEAD OF RARE DISEASE
1,275 @ $61.89$79K
Tax
2025-02-28
Rowland Thomas Andrew
SVP, HEAD - ESTABLISHED BRANDS
627 @ $61.89$39K
Sell10b5-1
2025-02-21
Davis Krista
SVP, CHIEF HR OFFICER
1,000 @ $60.20$60K
Tax
2025-02-15
Mutz Christopher
HEAD OF RARE DISEASE
1,184 @ $58.92$70K
Tax
2025-02-15
Gutwerg Ori
SVP, GENERICS
1,167 @ $58.92$69K
Tax
2025-02-14
Mutz Christopher
HEAD OF RARE DISEASE
1,473 @ $58.92$87K
Tax
2025-02-14
CAREY STEPHEN P.
SVP & CFO
1,730 @ $58.92$102K
Tax
2025-02-14
Lalwani Nikhil
PRESIDENT & CEO
7,799 @ $58.92$460K
Tax
2025-02-14
Davis Krista
SVP, CHIEF HR OFFICER
1,196 @ $58.92$70K
Tax
2025-02-14
Gutwerg Ori
SVP, GENERICS
1,426 @ $58.92$84K
Tax10b5-1
2025-02-14
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
1,434 @ $58.92$84K
Tax
2025-02-14
Rowland Thomas Andrew
SVP, HEAD - ESTABLISHED BRANDS
582 @ $58.92$34K
Sell10b5-1
2025-02-13
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
400 @ $59.54$24K
Grant
2025-02-12
Mutz Christopher
HEAD OF RARE DISEASE
24,808 @ ——
Grant10b5-1
2025-02-12
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
16,974 @ ——
Grant10b5-1
2025-02-12
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
11,316 @ ——
Grant
2025-02-12
Rowland Thomas Andrew
SVP, HEAD - ESTABLISHED BRANDS
7,834 @ ——
Grant
2025-02-12
Rowland Thomas Andrew
SVP, HEAD - ESTABLISHED BRANDS
5,222 @ ——
Grant
2025-02-12
Gutwerg Ori
SVP, GENERICS
15,668 @ ——
Grant
2025-02-12
Gutwerg Ori
SVP, GENERICS
10,444 @ ——
Grant
2025-02-12
Gassert Chad
SVP - CORP. DEV. & STRATEGY
14,362 @ ——
Grant
2025-02-12
Gassert Chad
SVP - CORP. DEV. & STRATEGY
9,574 @ ——
+ 11 more
← All catalysts for $ANIP